Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurovascular Diseases, Trauma, Mental Health {Anxiety Disorders, Epilepsy, and Others}, Degenerative Diseases {Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Cancer, and Others), by Drug Type (Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 131.3 million in 2021, and is expected to exhibit a CAGR of 6.4% during the forecast period (2021-2028).

Rising cases of central nervous system (CNS) disorders is expected to drive growth of the global central nervous system disorders therapeutics market during the forecast period. For instance, according to data published by Alzheimer’s Association in 2017, around 5.5 million people in the U.S. (all ages) suffered from Alzheimer’s dementia. Similarly, according to World Alzheimer Report of 2016, around 47 million people were living with dementia worldwide, and this statistics is expected to increase by three-fold and reach 131 million by 2050. Moreover, according to Alzheimer's disease Facts and Figures Report, in 2019, more than 5.8 million people in the U.S. were suffering from dementia associated with Alzheimer’s disease, out of which most of the patients were above the age of 75 years.

Market players are engaged in inorganic activities such as collaboration of companies, which is expected to drive growth of the global central nervous system disorders therapeutics market. For instance, in January 2019, Corbus Pharmaceuticals Holdings, Inc., a U.S. based pharmaceutical company collaborated with Kaken Pharmaceutical Co., a Japanese pharmaceutical company to commercialize its new product Lenabasum in Japan. Lenabasum is a compound used for treatment of systemic sclerosis.

Global Central Nervous System Disorders Therapeutics Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 186 million cases and 4.0 million deaths due to Coronavirus (COVID-19) were reported up till July 11, 2021 across the globe.

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the demand and supply in global central nervous system disorders therapeutics market. The COVID-19 pandemic has affected the demand and supply of global central nervous system disorders therapeutics market in three main ways; by directly affecting the production and demand of CNS disorder drugs; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities of neurological biomarkers in India, China, and the U.S. are disrupted due to nationwide lockdowns.

For instance, according to an article published by Clinical trial arena in January 2021, around 84% of patients suffering from severe COVID-19 infection are reported to experience some kind of cognitive impairment such as mental confusion. This study reveals that COVID-19 patients are at a higher risk of acquiring a neurological disorder such as dementia and Alzheimer’s disease. Thus, COVID-19 pandemic is expected to increase the demand of central nervous system disorders therapeutics for treatment of CNS disorders associated with COVID-19 infection.

Browse 32 Market Data Tables and 25 Figures spread through 170 Pages and in-depth TOC on Global Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurovascular Diseases, Trauma, Mental Health {Anxiety Disorders, Epilepsy, and Others}, Degenerative Diseases {Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Cancer, and Others), by Drug Type (Analgesics, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global central nervous system disorders therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/central-nervous-system-disorders-therapeutics-market-4544

Moreover, launch of new CNS disorder drugs and approvals is expected to drive the global central nervous system disorders therapeutics market growth. For instance, in April 2020, Neurocrine Biosciences, Inc., a U.S. based biopharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for its drug Ongentys used to treat Parkinson’s disease.

Key Takeaways of the Global Central Nervous System Disorders Therapeutics Market:

  • The global central nervous system disorders therapeutics market is expected to exhibit a CAGR of 6.4% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028) owing to rising number of product launches. For instance, in October 2019, Biogen, a U.S. based biotechnology company and Alkermes plc, an Ireland based biopharmaceutical company received the U.S. FDA approval for their drug VUMERITY which is used for treatment of multiple Multiple sclerosis drugs is expected to be the fastest growing segment in the central nervous system disorders therapeutics market due to rising cases of multiple sclerosis. Furthermore, according to the national multiple sclerosis society data 2020, there are approximately 2.8 million people around the world who were suffering from multiple sclerosis in 2020.
  • Some of the major players operating in the global central nervous system disorders therapeutics market include Pfizer Inc., Biogen, Otsuka Pharmaceutical Co. Ltd., Merck & Co., AstraZeneca, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Private Limited, Eli Lilly and Company, Sanofi, GlaxoSmithKline plc., and Boehringer Ingelheim International GmbH
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.